Literature DB >> 15846269

Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study.

Anne B Curtis1, A Allen Seals, Robert E Safford, William Slater, Nicholas G Tullo, Humberto Vidaillet, David J Wilber, April Slee.   

Abstract

OBJECTIVE: The objective of the current study was to determine the clinical factors that were associated with abandonment of a rate-control or a rhythm-control strategy in patients with atrial fibrillation (AF).
BACKGROUND: Although the AFFIRM Study demonstrated that outcomes are similar with a primary strategy of rate-control or rhythm-control for AF, there may be clinical or demographic factors associated with abandonment of the initial treatment strategy. Knowledge of these risk factors would be useful so that patients may be given appropriate initial therapy and, as appropriate, switched to alternative treatments earlier.
METHODS: Patients in the AFFIRM Study were subdivided into those who were maintained on their initial treatment strategy versus those who abandoned initial treatment strategy for alternative therapies. We determined the clinical and demographic factors associated with change in initial treatment strategy.
RESULTS: At 5 years the original treatment strategy was maintained in 85% of the patients in the rate-control arm versus 62% of those in the rhythm-control arm (P <.0001). Length of the qualifying episode of AF was associated with abandonment of both rhythm-control and rate-control strategies. Antiarrhythmic drug failure before randomization and a history of thyroid disease also were associated with abandonment of rhythm-control. Patients were more likely to maintain rate-control if they already had an implanted pacemaker or if they were older than 75 years, while an ejection fraction <30% was associated with abandonment of the rate-control strategy.
CONCLUSIONS: In patients with AF, rhythm-control strategies are abandoned significantly more often than rate-control strategies. Patients with long durations of AF on presentation or previous antiarrhythmic drug failure might be considered for rate-control as initial treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846269     DOI: 10.1016/j.ahj.2004.08.012

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Pharmacologic Rate versus Rhythm Control for Atrial Fibrillation in Heart Failure Patients.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Virginia Mplani; Maria Anastasopoulou; Nicholas Kounis; Cesare de Gregorio; Grigorios Tsigkas; Arun Karunakaran; Panagiotis Plotas; Ignatios Ikonomidis
Journal:  Medicina (Kaunas)       Date:  2022-05-30       Impact factor: 2.948

3.  Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).

Authors:  Karl-Heinz Kuck; Dmitry S Lebedev; Evgeny N Mikhaylov; Alexander Romanov; László Gellér; Oskars Kalējs; Thomas Neumann; Karapet Davtyan; Young Keun On; Sergey Popov; Maria Grazia Bongiorni; Michael Schlüter; Stephan Willems; Feifan Ouyang
Journal:  Europace       Date:  2021-03-08       Impact factor: 5.214

4.  Drug therapy in atrial fibrillation management: where do we stand in 2010?

Authors:  Gholamreza Davoodi; Mehdi Montazeri
Journal:  J Tehran Heart Cent       Date:  2010-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.